OncoTherapy Science, Inc. (4564.T)
Tokyo · JPY · Healthcare · Biotechnology
¥17 (+0.00%) as of
Key statistics
- Market cap
- 6.94B
- Forward P/E
- -0.83
- EPS (TTM)
- -2.37
- Dividend yield
- 0.00%
- 52-week range
- 17.00 – 34.00
- Beta
- 0.30
- Revenue (TTM)
- 777M
- Profit margin
- -113.77%
- Volume
- 173.86M
About OncoTherapy Science, Inc.
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. Its pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, the company is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Kawasaki, Japan
- Employees
- 46
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.